https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-september-7-2026/ 2026-09-07T22:01:33Z Pharminent en Rare Disease & Gene Therapy Digest • September 7, 2026 2026-09-07T22:01:31Z Blog https://pharminent.com/novartis-and-ioniss-pelacarsen-lowers-lpa-but-misses-on-cardiovascular-outcomes/ 2026-09-07T20:45:06Z Pharminent en Novartis and Ionis' Pelacarsen Lowers Lp(a) but Misses on Cardiovascular Outcomes 2026-09-07T19:42:12Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-7-2026/ 2026-09-07T17:40:13Z Pharminent en Strategic News Watch • September 7, 2026 2026-09-07T17:40:11Z Blog https://pharminent.com/uks-claret-capital-raises-575m-for-european-biotechs/ 2026-09-07T19:23:28Z Pharminent en UK's Claret Capital raises 575m for European biotechs 2026-09-07T13:04:30Z Blog https://pharminent.com/major-trial-of-roche-alzheimers-drug-kicks-off-in-europe/ 2026-09-07T19:15:44Z Pharminent en Major trial of Roche Alzheimer's drug kicks off in Europe 2026-09-07T09:07:12Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-september-5-2026/ 2026-09-07T00:04:05Z Pharminent en Week in Review • INTELLIGENCE BRIEF • September 5, 2026 2026-09-07T00:04:02Z Blog https://pharminent.com/pro-hub-locked/ 2026-09-06T02:10:32Z Pharminent en Pro Hub — Members Only 2026-09-06T02:10:29Z Blog